Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
mi
from 91732
Lutherville, MD
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
mi
from 91732
Lutherville, MD
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2281
mi
from 91732
Silver Spring, MD
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2281
mi
from 91732
Silver Spring, MD
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1964
mi
from 91732
Troy, MI
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1964
mi
from 91732
Troy, MI
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1341
mi
from 91732
Kansas City, MO
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1341
mi
from 91732
Kansas City, MO
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1485
mi
from 91732
Mexico, MO
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1485
mi
from 91732
Mexico, MO
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1254
mi
from 91732
Lincoln, NE
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1254
mi
from 91732
Lincoln, NE
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2409
mi
from 91732
Cedar Knolls, NJ
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2409
mi
from 91732
Cedar Knolls, NJ
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2447
mi
from 91732
Great Neck, NY
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2447
mi
from 91732
Great Neck, NY
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2435
mi
from 91732
New York, NY
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2298
mi
from 91732
Jacksonville, NC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2298
mi
from 91732
Jacksonville, NC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2214
mi
from 91732
Raleigh, NC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2214
mi
from 91732
Raleigh, NC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
2104
mi
from 91732
Columbia, SC
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
2104
mi
from 91732
Columbia, SC
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1600
mi
from 91732
Germantown, TN
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1600
mi
from 91732
Germantown, TN
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1763
mi
from 91732
Nashville, TN
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
592
mi
from 91732
Ogden, UT
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
592
mi
from 91732
Ogden, UT
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
959
mi
from 91732
Bellevue, WA
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
959
mi
from 91732
Bellevue, WA
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
939
mi
from 91732
Spokane, WA
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
939
mi
from 91732
Spokane, WA
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1720
mi
from 91732
West Bend, WI
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1720
mi
from 91732
West Bend, WI
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Site Reference ID/Investigator# 22507
8195
mi
from 91732
Bedford Park,
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Site Reference ID/Investigator# 22507
8195
mi
from 91732
Bedford Park,
Click here to add this to my saved trials
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated:  4/26/2017
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
Status: Enrolling
Updated: 4/26/2017
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics
Status: Enrolling
Updated:  5/3/2017
Cincinnati Children's Hospital Medical Center
1880
mi
from 91732
Cincinnati, OH
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics
Status: Enrolling
Updated: 5/3/2017
Cincinnati Children's Hospital Medical Center
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated:  5/4/2017
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated: 5/4/2017
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated:  5/4/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)
Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-TNF Users (VERVE)
Status: Enrolling
Updated: 5/4/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Vitamin D Supplementation in Warfighters
Genomics of Vitamin D Supplementation and Warfighter Nutritional Resilience
Status: Enrolling
Updated:  5/4/2017
Madigan Army Medical Center
941
mi
from 91732
Tacoma, WA
Vitamin D Supplementation in Warfighters
Genomics of Vitamin D Supplementation and Warfighter Nutritional Resilience
Status: Enrolling
Updated: 5/4/2017
Madigan Army Medical Center
941
mi
from 91732
Tacoma, WA
Click here to add this to my saved trials
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated:  5/8/2017
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated: 5/8/2017
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated:  5/8/2017
Michael E. Debakey VA Medical Center
1357
mi
from 91732
Houston, TX
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
Status: Enrolling
Updated: 5/8/2017
Michael E. Debakey VA Medical Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Mayo Clinic Arizona
356
mi
from 91732
Scottsdale, AZ
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Mayo Clinic Arizona
356
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Desert Sun Clinical Research, LLC
426
mi
from 91732
Tucson, AZ
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Desert Sun Clinical Research, LLC
426
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Alliance Clinical Research
73
mi
from 91732
Oceanside, CA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Alliance Clinical Research
73
mi
from 91732
Oceanside, CA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Precision Research Institute, LLC
105
mi
from 91732
San Diego, CA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Precision Research Institute, LLC
105
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
University of Colorado, School of Medicine
825
mi
from 91732
Aurora, CO
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
University of Colorado, School of Medicine
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Connecticut Clinical Research Foundation
2483
mi
from 91732
Bristol, CT
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Connecticut Clinical Research Foundation
2483
mi
from 91732
Bristol, CT
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
University of Florida
2104
mi
from 91732
Gainesville, FL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
University of Florida
2104
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Borland-Groover Clinic
2135
mi
from 91732
Jacksonville, FL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Borland-Groover Clinic
2135
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Children's Center for Digestive Healthcare
1918
mi
from 91732
Atlanta, GA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Children's Center for Digestive Healthcare
1918
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Grand Teton Research Group
721
mi
from 91732
Idaho Falls, ID
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Grand Teton Research Group
721
mi
from 91732
Idaho Falls, ID
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Northwestern University Feinberg School of Medicine
1730
mi
from 91732
Chicago, IL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Northwestern University Feinberg School of Medicine
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Southwest Gastroenterology
1722
mi
from 91732
Oak Lawn, IL
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Southwest Gastroenterology
1722
mi
from 91732
Oak Lawn, IL
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Indiana University
1791
mi
from 91732
Indianapolis, IN
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Indiana University
1791
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
University of Iowa Hospitals and Clinics
1528
mi
from 91732
Iowa City, IA
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
University of Iowa Hospitals and Clinics
1528
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Gastroenterology and Hepatology Service Walter Reed National Military Medical Center
2277
mi
from 91732
Bethesda, MD
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Gastroenterology and Hepatology Service Walter Reed National Military Medical Center
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
2278
mi
from 91732
Chevy Chase, MD
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
2278
mi
from 91732
Chevy Chase, MD
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan
1836
mi
from 91732
Wyoming, MI
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan
1836
mi
from 91732
Wyoming, MI
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Minnesota Gastroenterology, P.A.
1501
mi
from 91732
Plymouth, MN
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Minnesota Gastroenterology, P.A.
1501
mi
from 91732
Plymouth, MN
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
GI Associates and Endoscopy Center-GI Clinical Research Department
1611
mi
from 91732
Flowood, MS
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
GI Associates and Endoscopy Center-GI Clinical Research Department
1611
mi
from 91732
Flowood, MS
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Darthmouth-Hitchcock Medical Center
2515
mi
from 91732
Lebanon, NH
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Darthmouth-Hitchcock Medical Center
2515
mi
from 91732
Lebanon, NH
Click here to add this to my saved trials
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated:  5/8/2017
Asheville Gastroenterology Associates, P.A.
2002
mi
from 91732
Asheville, NC
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status: Enrolling
Updated: 5/8/2017
Asheville Gastroenterology Associates, P.A.
2002
mi
from 91732
Asheville, NC
Click here to add this to my saved trials